Power at the Top of Health Care in America

If the U.S. health care system were a country, it would have one of the biggest economies on Earth.
We spend trillions of dollars every year trying to stay alive, stay comfortable, and sometimes just
get someone to call us back with test results. With that much money on the table, it’s only natural
to ask a very simple question:

Who actually holds the power at the top of health care in America?

Spoiler: it’s not your primary care doctor, and it’s definitely not you, the person in the paper gown.
The real power players are a tangled mix of giant hospital systems, health insurers, pharmacy benefit
managers (PBMs), pharmaceutical and device companies, and government programs like Medicare and Medicaid.
Together, they shape what care you get, how much you pay, and what choices you actually have.

Follow the Money: The $4.6 Trillion Question

The U.S. health care market was valued at roughly $4.6 trillion in 2024 and is projected
to grow steadily over the next decade. That’s not just “big industry” that’s an entire power structure
built around who captures which slice of that giant pie.

Broadly, the money flows through a few major channels:

• Hospitals and health systems – They deliver inpatient and outpatient care and now control a growing share of physicians.
• Health insurers – They collect premiums from employers, individuals, and the government, and decide what’s covered.
• Pharmacy Benefit Managers (PBMs) – The middlemen negotiating drug prices and formularies behind the scenes.
• Pharmaceutical and device companies – They develop drugs and technology and fiercely protect their patents and prices.
• Government programs – Medicare, Medicaid, the VA, and regulators like the FTC, CMS, and state insurance departments.

Power in health care is mostly about control over prices, payment rules, and access. Let’s look at who’s
doing what at the top of the system.

Hospitals and Health Systems: Local Empires with Regional Power

Hospitals used to be more like community fixtures some independent, some religious, some academic.
Today, many of them belong to sprawling health systems that own multiple hospitals, outpatient centers,
clinics, and sometimes even their own insurance plans.

Consolidation Gives Systems Serious Leverage

Over the past decade, hospitals and physician practices have been steadily consolidating. When a hospital
system becomes the dominant provider in a region, it gains powerful leverage over commercial insurers.
Research has shown that when a system’s local market share increases, the prices it negotiates with
insurers for hospital admissions tend to rise significantly hundreds of dollars more per admission,
often for the exact same service and quality level.

That bargaining power doesn’t just sit on a spreadsheet. It shows up as higher premiums and out-of-pocket
costs for employers and families. In many metro areas, a handful of hospital systems essentially set the
going rate for care, and insurers either pay up or risk having very few hospitals in their network.

“Nonprofit” Doesn’t Mean “Not Powerful”

A large share of U.S. hospitals are technically nonprofit. That status brings tax advantages and the
requirement to provide community benefits, but it doesn’t mean they’re small or weak. Many nonprofit
systems run like major corporations, with multi-billion-dollar budgets, sophisticated investment portfolios,
and executive pay packages that look more like Fortune 500 than charity.

Their power is highly local and regional. If you live in a city where one system owns the biggest hospitals
and most specialist practices, that system effectively controls your realistic options for complex care.

Health Insurers: The Gatekeepers of Coverage

On the other side of the bargaining table sit the health insurers national giants like UnitedHealth Group,
Humana, CVS/Aetna, and Elevance, plus a mix of regional Blues plans and smaller carriers. Together, they
manage over a trillion dollars in premiums each year.

Big Carriers, Big Market Share

Health insurance is highly concentrated. In many states, the largest three insurers control most of the
large-group market. Nationally, UnitedHealth alone writes hundreds of billions of dollars in premiums
annually and continues to expand through both insurance and health services arms.

The power of insurers shows up in several ways:

• Network design: Insurers decide which hospitals and doctors are “in network.” If your favorite
  specialist isn’t, your wallet will feel it.
• Prior authorizations: Want an MRI, a specialty drug, or certain surgeries? Often you need the insurer’s
  approval first. That’s real power over clinical decisions.
• Plan design and cost-sharing: Insurers help employers decide on deductibles, copays, and covered services.
  Those design choices shape whether people seek care at all.

Medicare Advantage: Private Plans, Public Dollars

Another major source of insurer power is Medicare Advantage (MA) private insurance plans that deliver
Medicare benefits. More than half of Medicare beneficiaries are now in MA plans, and enrollment continues
to grow. In many counties, three big insurers dominate MA enrollment.

When private plans control such a large portion of publicly funded seniors’ coverage, they gain a powerful
voice in how benefits are structured, how providers are paid, and what kinds of care models get scaled.
They also earn substantial revenue (and sometimes strong margins) from these government contracts, giving
them both financial and policy influence.

PBMs: The Invisible Middlemen in Your Pharmacy Bill

If hospitals and insurers are the visible giants, pharmacy benefit managers (PBMs) are the powerful
middlemen lurking in the fine print. PBMs sit between drug manufacturers, insurers, pharmacies, and
employers. They manage prescription drug benefits, negotiate rebates, and decide which drugs are preferred
on formularies.

Three big PBMs CVS Caremark, Express Scripts, and OptumRx control the majority of the market. They’re
often vertically integrated with large insurers and pharmacy chains. That level of integration gives them
enormous control over:

• Which drugs are covered and at what tier (and thus what you pay at the pharmacy counter).
• How much employers and health plans spend on drugs overall.
• Which pharmacies get favorable contracts often steering patients toward mail-order or chain-owned pharmacies.

Critics argue that PBM practices like spread pricing, opaque rebates, and steering can raise overall costs
while making it hard to see where the money actually goes. Regulators and Congress have increasingly
focused on PBMs as key power brokers in drug pricing, not just neutral negotiators.

Pharma and Device Companies: Science, Patents, and Policy Muscle

Pharmaceutical and medical device companies wield a different kind of power: control over the products
that can literally change or save lives. When they bring a breakthrough cancer therapy or gene
treatment to market, they often do so under strong patent protections that allow high prices for years.

Pricing Power Backed by Patents

U.S. policy allows drug makers to set launch prices with relatively limited direct regulation, especially
compared with many other wealthy countries. Once a high list price hits the market, negotiations through
PBMs and insurers may lower net prices somewhat, but patients often still feel the pain in deductibles,
coinsurance, or cash prices.

As a result, drug makers occupy a powerful position: they control access to therapies people desperately
need, and they operate within a system that tolerates some of the highest drug prices in the world.

Lobbying and Influence

The pharmaceutical and health products industry routinely ranks among the top lobbying spenders in
Washington. Trade groups and companies push hard on issues like patent protections, Medicare drug price
negotiations, research incentives, and FDA policy. When you combine patent power with political influence,
you get a sector that can strongly shape the rules of the game.

Government: Referee, Financier, and Sometimes Player

The U.S. government wears multiple hats in health care:

• Financier: Through Medicare, Medicaid, the Children’s Health Insurance Program (CHIP), the VA, and federal employee plans, government pays for a huge share of total health spending.
• Regulator: Agencies like CMS, the FTC, FDA, and state insurance departments set rules about safety, competition, coverage, and payment.
• Customer and negotiator: Especially in Medicare drug price negotiations and Medicaid rebates, government is a very large customer with growing bargaining power.

But unlike some countries where government directly runs most care delivery, the U.S. mostly funds and
regulates a private system. That means much of the power remains with private corporations hospitals,
insurers, PBMs, drug companies whose first obligations are to their boards, investors, and long-term
financial stability.

So Who Really Holds Power at the Top?

In reality, power in U.S. health care is distributed but concentrated. A relatively small number of
large organizations in each sector play oversized roles:

• In many regions, a handful of health systems dominate hospital and specialty care.
• A small set of national insurers and MA plans control huge portions of commercial and senior coverage.
• Three PBMs control most prescription benefit management.
• Large pharma and device firms control high-value therapies and invest heavily in lobbying.

Patients and even individual doctors often feel like they’re at the bottom of a very tall pyramid, where
decisions about cost, coverage, and access get made far above their heads.

What This Power Imbalance Looks Like in Real Life

You see this power dynamic every time:

• Your doctor says a treatment is the best option, but your plan requires you to “fail” a cheaper drug first.
• You get a surprise out-of-network bill because one part of your care team didn’t take your insurance, even though you never chose them.
• Your pharmacy suddenly tells you that the inhaler you’ve used for years is no longer covered but another brand “almost the same” is.
• Your local independent hospital merges into a system, and within a year, prices and facility fees creep up.

None of that happens by accident; it happens because powerful organizations are negotiating and designing
the rules in ways that align with their financial goals even when they also genuinely care about health
outcomes.

What a More Balanced System Could Look Like

Shifting power toward patients and communities doesn’t mean eliminating large institutions (you probably
want a large, well-equipped hospital for your open-heart surgery). It does mean:

• More transparency around prices, PBM rebates, and contracts.
• Stronger antitrust enforcement to keep any one system or insurer from becoming too dominant in a region.
• Payment models that reward outcomes rather than just volume of services.
• Policy guardrails on extreme price hikes or exploitative practices.

Some of these changes are already in motion through new laws, regulatory crackdowns on anticompetitive
behavior, and experiments in value-based care. But there’s still a long way to go before the average
person feels like the system works for them instead of on them.

How Patients and Clinicians Can Push Back (At Least a Little)

No, you can’t personally out-negotiate a trillion-dollar insurance conglomerate. But you’re not totally
powerless either:

• Ask for upfront cost estimates and shop around for elective services when possible.
• Appeal denials many get overturned when challenged.
• Use in-network and preferred providers strategically to avoid surprise costs.
• Support policy changes that improve transparency and competition, such as site-neutral payments or PBM reform.
• Clinicians can join hospital, insurer, and policy advisory groups where care delivery rules are shaped.

It’s not a fair fight, but sunlight, data, and collective pressure can chip away at the most abusive parts
of the system and rebalance power slowly, stubbornly, and sometimes surprisingly.

Experiences from the Front Lines of Power in U.S. Health Care

Power structures can feel abstract until you’re the one juggling bills, phone calls, and prior
authorizations. Here are a few real-world style scenarios that capture what “power at the top” looks
like from the ground.

1. Maria and the Mystery Bill

Maria, a 42-year-old teacher with employer-sponsored insurance, goes to the ER for alarming chest pain.
Thankfully, it turns out to be a severe case of acid reflux. A stressful night, but no heart attack great
news. A month later, she gets an eye-watering bill for an out-of-network cardiologist she never realized
was involved in her care.

She did everything “right”: went to an in-network hospital, flashed her insurance card, followed directions.
What she didn’t control was the contracting relationship between her insurer and the physicians who
interpret tests in the background. Somewhere far above her, a negotiation failed, and now she’s caught in
the middle.

After several phone calls, a denied appeal, and some very patient hold music, the bill is reduced but not
erased. Maria isn’t just frustrated with the money she feels powerless in a system where invisible
contract terms can matter more than medical need.

2. Dr. Lee and the Prior Authorization Wall

Dr. Lee is a family physician who spends as much time fighting with prior authorization systems as she does
talking to patients. When she prescribes a newer, more effective medication for a chronic condition, the
pharmacy often sends a message: “Not covered alternative preferred.”

That “alternative” is chosen not by her, but by the PBM and insurer, based on their negotiated deals. If
Dr. Lee really wants the original drug, she has to fill out forms, attach chart notes, and wait for a
decision. Multiply this process across dozens of patients and drugs, and you get a daily reminder of where
practical power lies.

Clinically, she knows what’s best for many patients. Systemically, she has to negotiate with algorithms and
formularies built by organizations that may never meet those patients but definitely see their data and
cost profiles.

3. James and Medicare Advantage Fine Print

James, 70, switches from traditional Medicare to a Medicare Advantage plan after seeing ads promising extra
benefits like vision, dental, and a fitness membership. At first, it feels like a great deal. Premiums are
low, his gym is covered, and his medications are affordable.

Then James develops a more serious heart condition. Suddenly, the trade-offs become clearer: fewer
available cardiologists in-network, more prior authorizations, and subtle nudges toward lower-cost care
settings. For every test and referral, there’s an approval step, a network rule, or a utilization review.

James doesn’t hate his plan far from it. But he realizes the real power lies with the plan’s benefit
design and network rules. Those decisions were made years earlier in boardrooms and regulatory filings,
long before he ever saw a friendly TV commercial.

4. A Nurse’s View from the Inside

For Ashley, a hospital nurse, power looks like staffing ratios and budget decisions. When her health
system merges with a larger regional chain, there are promises of “efficiency” and “standardization.”
Over time, she notices more pressure to move patients through quickly, fewer support staff on night shifts,
and more metrics on her performance dashboard.

None of that is decided by the bedside. It’s decided by executives responding to financial targets, payer
contracts, and system-level strategies. Ashley cares deeply about her patients, but she also knows that
if her unit isn’t hitting productivity and length-of-stay goals, someone in a suit will show up to ask why.

Her experience underscores a key reality: even when individual clinicians want to give more time,
more empathy, or more flexibility, structural power often constrains what they can do.

What These Stories Have in Common

Maria, Dr. Lee, James, and Ashley sit at different points in the system patient, doctor, senior, nurse.
Yet they all run into the same invisible forces: networks, contracts, formularies, staffing models, and
financial incentives decided far above their pay grade.

Their experiences don’t mean the system is hopeless. But they do reveal why conversations about health
care reform can’t stop at “shop for cheaper care” or “live a healthier lifestyle.” Personal choices matter,
but so do the concentrated economic and political forces at the top of health care in America. Understanding
those forces is the first step toward changing them or at least making them a little more accountable to
the people whose lives and wallets are on the line.

Conclusion

Power in American health care isn’t held by one villainous group. It’s shared and sometimes fought over
by giant health systems, insurers, PBMs, drug and device makers, and government payers. Each has a legitimate
role, but each also has strong financial incentives that don’t always line up with what patients and
communities need most.

If there’s a hopeful note, it’s this: the more we understand who actually makes the rules, the easier it
becomes to ask better questions, support smarter reforms, and push for a system where power serves health,
not just balance sheets.